93 related articles for article (PubMed ID: 19737278)
1. Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation.
Gat Y; Joshua S; Gornish MG
Andrologia; 2009 Oct; 41(5):305-15. PubMed ID: 19737278
[TBL] [Abstract][Full Text] [Related]
2. Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment.
Gat Y; Gornish M; Heiblum M; Joshua S
Andrologia; 2008 Oct; 40(5):273-81. PubMed ID: 18811916
[TBL] [Abstract][Full Text] [Related]
3. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
4. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients.
Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L
Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
8. Benign Prostatic Hyperplasia: Long-term follow-up of prostate volume reduction after sclerotherapy of the internal spermatic veins.
Gat Y; Goren M
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28948696
[TBL] [Abstract][Full Text] [Related]
9. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
10. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
11. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
[TBL] [Abstract][Full Text] [Related]
12. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
14. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
[TBL] [Abstract][Full Text] [Related]
15. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
17. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
18. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
19. Soy isoflavones in the treatment of prostate cancer.
Hussain M; Banerjee M; Sarkar FH; Djuric Z; Pollak MN; Doerge D; Fontana J; Chinni S; Davis J; Forman J; Wood DP; Kucuk O
Nutr Cancer; 2003; 47(2):111-7. PubMed ID: 15087261
[TBL] [Abstract][Full Text] [Related]
20. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
